Pluvicto
Evidence Grade A — Regulatory approved. 16 published studies. 13 registered clinical trials.
Loading...
Lutetium Lu-177 vipivotide tetraxetan (sold as Pluvicto) is a targeted radiation treatment for advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. Like Lutathera, it uses a molecular homing system — but instead of finding neuroendocrine tumour receptors, it seeks out PSMA, a protein found at very high levels on prostate cancer cells. It is given as six intravenous infusions, six weeks apart.
16 published studies: 11 human, 0 animal, 0 in-vitro, 8 reviews
Pluvicto is marketed by Novartis (approved March 2022) for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) in adults who have already received hormone-targeting therapy and taxane chemotherapy. Administered as six intravenous infusions every 6 weeks.
The VISION trial showed Pluvicto extended overall survival by 4 months (15.3 versus 11.3 months) and more than doubled the time before disease worsened compared to standard care alone. Patients must have PSMA-positive tumours confirmed by a companion PET scan before treatment. The PSMAfore trial subsequently showed benefit in patients who had not yet received chemotherapy, potentially expanding the eligible population. Supply constraints limited availability in the first year after approval.
PSMA is a protein found on the surface of prostate cancer cells at concentrations 100 to 1,000 times higher than on normal tissue, and its expression increases as the cancer becomes more aggressive. Pluvicto's targeting molecule binds to PSMA's active site with high precision. Once bound, the entire complex is pulled inside the cancer cell, where the lutetium-177 emits targeted beta radiation that damages the cell's DNA. The radiation's short range (less than 1mm mean penetration) focuses the destructive energy on the tumour while sparing most surrounding tissue.
The VISION trial showed Pluvicto extended overall survival by 4 months (15.3 versus 11.3 months) and more than doubled the time before disease worsened in men with heavily pre-treated prostate cancer. Patients must have PSMA-positive tumours confirmed by a companion PET scan before treatment can begin. A subsequent trial (PSMAfore) showed benefit in patients who had not yet received chemotherapy, potentially expanding the eligible population substantially. Another trial (PSMAddition) is studying use even earlier, in combination with standard hormone therapy. The main side effects include anaemia, fatigue, dry mouth, and bone marrow suppression, with a small long-term risk of secondary blood cancers. Supply constraints limited availability in the first year after approval but have since improved.
PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer
Post Marketing Study on Pluvicto in Korea
FDA ORIG 1
EMA Marketing Authorisation
FDA SUPPL 24
FDA SUPPL 21
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
